N@N

Christopher Raymond Maintained (AMGN) at Buy with Decreased Target to $288 on, Apr 28th, 2023

^{Published on 2024-10-28 03:10:45 - WOPRAI, Christopher Raymond}
 

Christopher Raymond of Piper Sandler, Maintained "Amgen Inc." (AMGN) at Buy with Decreased Target from $293 to $288 on, Apr 28th, 2023.

Christopher has made no other calls on AMGN in the last 4 months.

There are 9 other peers that have a rating on AMGN. Out of the 9 peers that are also analyzing AMGN, 4 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Robyn Karnauskas of "Truist Securities" Maintained at Hold with Decreased Target to $260 on, Monday, February 13th, 2023
• David Risinger of "SVB Leerink" Maintained at Hold with Decreased Target to $267 on, Thursday, February 2nd, 2023
• Evan David Seigerman of "BMO Capital" Maintained at Hold with Decreased Target to $253 on, Wednesday, February 1st, 2023
• Gregory Renza of "RBC Capital" Maintained at Hold with Decreased Target to $258 on, Wednesday, February 1st, 2023

These are the ratings of the 5 analyists that currently disagree with Christopher

---

• Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $290 on, Monday, April 24th, 2023
• Carter Gould of "Barclays" Maintained at Sell with Decreased Target to $227 on, Friday, April 14th, 2023
• Mohit Bansal of "Wells Fargo" Upgraded from Hold to Buy and Decreased Target to $265 on, Monday, March 13th, 2023
• Trung Huynh of "Credit Suisse" Maintained at Sell with Decreased Target to $220 on, Wednesday, February 1st, 2023
• Yaron Weber of "Cowen & Co." Maintained at Buy with Decreased Target to $289 on, Wednesday, February 1st, 2023

Contributing Sources

---